Company Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.
The company’s lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation.
In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency.
Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Ronald Martell |
Contact Details
Address: 2200 Bridge Pkwy, Suite 102 Redwood City, California 94065 United States | |
| Phone | 650 549 1400 |
| Website | jaspertherapeutics.com |
Stock Details
| Ticker Symbol | JSPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001788028 |
| CUSIP Number | 471871103 |
| ISIN Number | US4718712023 |
| Employer ID | 84-2984849 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ronald A. Martell | President, Chief Executive Officer and Director |
| Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder and Director |
| Jeetinder Singh Mahal M.B.A. | Chief Operating Officer |
| Dr. Edwin Jonathan Tucker M.D. | Chief Medical Officer |
| Dr. Luca Di Noto Ph.D. | Senior Vice President of Technical Operations |
| David Ku M.D. | Vice President of Corporate Development, Portfolio Strategy and Management |
| Matthew Ford | Vice President of Human Resources |
| Dr. Wendy Pang M.D., Ph.D. | Senior Vice President of Research and Translational Medicine |
| Patricia Carlos | Senior Vice President of Regulatory Affairs and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 15, 2024 | 8-K | Current Report |
| Sep 12, 2024 | 144 | Filing |
| Aug 13, 2024 | 10-Q | Quarterly Report |